FDA warns eDrugstore over claims that compounded tirzepatide is FDA-approved, making drugs misbranded (falsely promoted).
What happened
In August 2025, FDA reviewed the website https://www.edrugstore.com and found it offered compounded drug products, including tirzepatide. FDA cited website claims such as “FDA-Approved Active” and a guarantee that all Tirzepatide medications are genuine, FDA-approved formulations. FDA says compounded drugs are not FDA-approved, so these claims are false or misleading and make the products “misbranded” (falsely or misleadingly labeled).
What FDA found
Website labeling claims falsely suggest the compounded tirzepatide is FDA-approved, which makes the drug misbranded.
FDCA section 502(a) [21 U.S.C. § 352(a)]Advertising and promotion of the compounded drug are false or misleading because they imply it is the same as an FDA-approved product such as Zepbound.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Introducing or delivering the misbranded drugs into interstate commerce is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also a prohibited act.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells eDrugstore to take immediate action to stop using the misleading claims and to send a written response within 15 working days describing the steps taken, how it will prevent recurrence, and supporting documentation.
Who should pay attention
- online pharmacies and telehealth companies selling compounded drugs
- marketers of compounded tirzepatide
- platforms that host or promote drug ads
This is a summary. Read the original letter on fda.gov.